Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determination of ultra-trace levels of uranium and thorium in electrolytic copper using radiochemical neutron activation analysis.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2021
Same author

Mid-life Crisis: Growth or Stagnation.

Canadian family physician Medecin de famille canadien·2010
Same author

Contemporary ethical dilemmas in psychotherapy: cosmetic psychopharmacology and managed care.

American journal of psychotherapy·1998
Same author

Managed care and academic psychiatry.

Journal of mental health administration·1993
Same author

Key issues in post-graduate psychiatric education in Canada.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·1986
Same author

Payment for psychiatric services under Canada's insurance system.

Hospital & community psychiatry·1985
Same journal

Tularaemia; a problem in diagnosis.

Canadian Medical Association journal·2010
Same journal

CONTROL of cancer.

Canadian Medical Association journal·2010
Same journal

Bilateral diphtheritic external otitis treated with sulfathiazole.

Canadian Medical Association journal·2010
Same journal

Hypoplastic anaemia treated with transfusions and folic acid fraction.

Canadian Medical Association journal·2010
Same journal

Lauron in rheumatoid arthritis; a further report.

Canadian Medical Association journal·2010
Same journal

HOW the socialist looks at national health service in England.

Canadian Medical Association journal·2010
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Pharmaceutical Product Information

H Prosen

    Canadian Medical Association Journal
    |March 24, 2010
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
    10:33

    An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

    Published on: May 24, 2024

    A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging
    05:51

    A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging

    Published on: March 17, 2023

    Related Experiment Videos

    Last Updated: Jun 14, 2026

    Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
    09:30

    Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

    Published on: March 17, 2023

    An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
    10:33

    An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

    Published on: May 24, 2024

    A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging
    05:51

    A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging

    Published on: March 17, 2023